Acadia Pharmaceuticals Inc. ACAD
Analyst Ratings
- Consensus
- Buy — 13 Buy · 2 Hold · 0 Sell (15 analysts)
- Avg. Price Target
- $34.73 (+23.0% upside)
Key Stats
- Today's Range
- $27.90 – $28.43
- 50-Day Range
- $20.84 – $29.85
- 52-Week Range
- $19.69 – $29.85
- Volume
- 1.06 million shs
- Average Volume
- 1.65 million shs
- Market Cap
- $5.07 billion
- P/E Ratio
- 12.66
- Dividend Yield
- —
Valuation
- P/E Ratio
- 12.66
- Price / Book
- 3.88
- Price / Sales
- 4.46
Short Interest
- Short Interest
- 5.74%
- Days to Cover
- 7.01
Financials (TTM)
- Revenue
- $1.14 billion
- Net Income
- $380.48 million
- Net Margin
- 33.42%
- Return on Equity
- 29.12%
- Debt-to-Equity
- —
About Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
Related Stocks
Compare head-to-head: ACAD vs LLY·ACAD vs JNJ·ACAD vs ABBV·ACAD vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.